More recently, a new platform, called ExoSearch, has been reported for the diagnosis of ovarian cancer in blood taking advantage of multiplexed measurements of three exosomal tumor markers (CA-125, EpCAM, CD24) while using a training set of ovarian cancer patient plasma, and showing diagnostic ability comparable with standard Bradford assay. Here, CD24 is linked to ovarian carcinoma.